GeNeuro SA

Equities

GNRO

CH0308403085

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-01-16 am EST			5-day change	1st Jan Change
0.0322 ^EUR	+6.62%		+8.78%	+2.55%

25-10-15	GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report	CI
25-10-15	Geneuro SA postpones publication of half-yearly financial report	RE

Geneuro: Eclosion2 falls below 20%.

Published on 01/13/2025 at 09:03 am EST - Modified on 01/13/2025 at 09:08 am EST

- Translated by Marketscreener - See original

GeNeuro SA

+6.62%

Eclosion2 SA, acting on behalf of the fund Eclosion2 & Cie SCPC, declared to the AMF that on January 8 it had crossed below the thresholds of 20% of the capital and voting rights in Geneuro, following the sale of shares on the market.

The declaring party stated that it held, on behalf of the said fund, 5,750,108 Geneuro shares representing the same number of voting rights, i.e. 19.32% of the capital and voting rights of this biotechnology company.

Copyright (c) 2025 CercleFinance.com. All rights reserved.

Latest news about GeNeuro SA

25-10-15	GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report	CI
25-10-15	Geneuro SA postpones publication of half-yearly financial report	RE
25-09-29	GeNeuro Secures Debt-restructuring Moratorium Extension from Swiss Court	MT
25-09-26	Geneuro SA announces extension of its definitive Debt Restructuring moratorium	RE
25-08-19	Eclosion2 Fund Reduces Stake in Geneuro Below 10%
25-07-16	Court Orders GeNeuro Subsidiary's Liquidation	MT
25-06-13	GeNeuro Subsidiary Placed in Receivership Amid Group Restructuring	MT
25-06-12	Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas	RE
25-05-28	GeNeuro Receives Debt-restructuring Moratorium from Swiss Court	MT
25-01-13	Geneuro: Eclosion2 falls below 20%.
24-09-30	GeNeuro SA Decides to Postpone the Publication of its June 30, 2024 Half-Yearly Results	CI
24-09-20	Geneuro: presentation of new Temelimab data
24-07-15	GeNeuro to Apply for Debt Moratorium in Switzerland	MT
24-07-15	GeNeuro: a procedure to restructure debt
24-06-28	GeNeuro: failure of phase 2 study in Covid long
24-06-28	GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome	CI
24-05-16	GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024	CI
24-03-20	Geneuro SA Announces Appointments of Board of Directors	CI
24-02-04	GeNeuro SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-02-02	GeNeuro: share price falls after private placement
24-02-02	GeNeuro Raises EUR5 Million from Share Issue	MT
24-01-08	GeNeuro appoints new Chief Medical Officer
24-01-05	Geneuro Sa Announces Executive Changes	CI
24-01-05	GeNeuro: Citigroup Global Markets Ltd crosses the 5% threshold
23-12-11	GeNeuro: positive opinion for continuation of trial

Chart GeNeuro SA

Duration

Period

GNRO: Dynamic Chart

Company Profile

GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.

Employees

Sector

Biotechnology & Medical Research

Calendar

Apr. 05 - Q4 2025 Earnings Release (Projected)

More about the company